ArticlemAbs2014
Effect of formulation on the stability and aerosol performance of a nebulized antibody.
Article in mAbs, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 87 citations in OpenAlex.
- Preferential apical infection and spread of human metapneumovirus highlights the importance of inhaled delivery of neutralizing monoclonal antibody to treat established infections.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- Respiratory delivered vaccines: Current status and perspectives in rational formulation design.Acta pharmaceutica Sinica. B · 2024Review
- Respiratory Delivery ofPharmaceutics · 2024Article
- Recent advances in extracellular vesicles for therapeutic cargo delivery.Experimental & molecular medicine · 2024Review
- Inhaled "Muco-Trapping" Monoclonal Antibody Effectively Treats Established Respiratory Syncytial Virus (RSV) Infections.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- Laminar Fluid Ejection for Olfactory Drug Delivery: A Proof of Concept Study.IEEE journal of translational engineering in health and medicine · 2024Article
- Stability Considerations for Bacteriophages in Liquid Formulations Designed for Nebulization.Cells · 2023Review
- Respiratory delivery of passive immunotherapies for SARS-CoV-2 prophylaxis and therapy.Human vaccines & immunotherapeutics · 2023Review
- Aerosol pulmonary immune engineering.Advanced drug delivery reviews · 2023Review
- Recent advances in respiratory immunization: A focus on COVID-19 vaccines.Journal of controlled release : official journal of the Controlled Release Society · 2023Review
- Exploring pulmonary distribution of intratracheally instilled liquid foams in excised porcine lungs.European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences · 2023Article
- Steps toward nebulization in-use studies to understand the stability of new biological entities.Drug discovery today · 2023Review
- Novel trehalose-based excipients for stabilizing nebulized anti-SARS-CoV-2 antibody.International journal of pharmaceutics · 2023Article
- Nebulization of extracellular vesicles: A promising small RNA delivery approach for lung diseases.Journal of controlled release : official journal of the Controlled Release Society · 2022Article
- Feasibility Studies of Nebulized SARS-CoV-2 Neutralizing Antibody in Mice and Cynomolgus Monkeys.Pharmaceutical research · 2022Article
- Aggregates Associated with Instability of Antibodies during Aerosolization Induce Adverse Immunological Effects.Pharmaceutics · 2022Article
- The future of inhalation therapy in chronic obstructive pulmonary disease.Current research in pharmacology and drug discovery · 2022Review
- Inhalation monoclonal antibody therapy: a new way to treat and manage respiratory infections.Applied microbiology and biotechnology · 2021Review
- A Narrative Review of a Pulmonary Aerosolized Formulation or a Nasal Drop Using Sera Containing Neutralizing Antibodies Collected from COVID-19-Recovered Patients as a Probable Therapy for COVID-19.Iranian journal of medical sciences · 2021Review
- Challenges and opportunities for antiviral monoclonal antibodies as COVID-19 therapy.Advanced drug delivery reviews · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 6 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Most monoclonal antibodies (mAbs) are administered to patients intravenously to ensure high bioavailability as rapidly as possible. The airways, however, are an attractive delivery route for mAbs for the treatment of lung diseases, making it possible to increase their concentration in the target organ while limiting their systemic passage. Several challenges must be overcome for translation into clinical practice. For example, the drug and device must be paired for the efficient and reliable deposition of a pharmacologically active and safe mAb in the lung region of interest. Mesh nebulizers appear to be the most effective aerosol-producing devices for delivering large amounts of biopharmaceutical while limiting protein instability during nebulization. We used metrological and analytic methods to analyze the effect of both antibody concentration and surfactant addition on aerosol performance and antibody integrity. These two factors had a limited effect on aerosol performance, but affected antibody aggregation. The addition of surfactants to antibody formulations at concentrations appropriate for lung administration markedly reduced the formation of medium or large aggregates, as shown by dynamic light scattering and fluorescence microscopy. Aggregation was also dependent on the type of mesh nebulizer, highlighting the need to optimize drug and device together.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.